Drug Profile
MC 02479
Alternative Names: RWJ 54428Latest Information Update: 07 Feb 2007
Price :
$50
*
At a glance
- Originator Essential Therapeutics [CEASED]
- Developer Essential Therapeutics [CEASED]; Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Antibacterials; Cephalosporins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections